Prazer Therapeutics
- Biotech or pharma, therapeutic R&D
Prazer is a Korean biotech company developing orally available, BBB-penetrating protein degraders with a novel approach in targeted protein degradation (TPD). The company aims to tackle the limitations of traditional bivalent and monovalent degraders, such as PROTACs and molecular glues, by identifying novel degrading mechanisms through its proprietary TPD platform, SPiDEM. Prazer is focused on developing protein degraders for a wide range of intractable diseases in neuroscience, oncology, and immunology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}